Disease Activity-Related Sleep Dysfunction in Psoriasis: Insights from a Cross-Sectional Study

Background/Objectives: Psoriasis (PsO) is a chronic immune-mediated disease associated with a substantial multidimensional burden extending beyond skin involvement. Sleep disturbance represents an important yet underexplored domain of patient-reported outcomes. This study aimed to investigate the relationship between PsO disease activity and sleep quality, focusing on specific sleep domains, and to evaluate whether disease severity independently predicts sleep latency and daytime dysfunction. Methods: We conducted a cross-sectional study including 136 consecutive patients with PsO from two Italian centers. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI). Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI), while quality of life was measured by the SF-36. Patients were stratified according to disease severity (PASI < 10 vs. ≥10). Associations between disease activity and sleep domains were analyzed using univariable and multivariable ordinal regression models adjusted for demographic and clinical variables. Results: The study population had predominantly low disease activity (median PASI 2). The median global PSQI score was 5, indicating overall borderline sleep impairment. Patients with PASI ≥ 10 showed significantly worse sleep latency (p = 0.01) and greater daytime dysfunction (p = 0.02), while no significant differences were observed in global PSQI scores. In multivariable analyses, PASI ≥ 10 remained independently associated with increased sleep latency (β = 0.95, 95% CI 0.08–1.82; p = 0.032) and daytime dysfunction (β = 2.52, 95% CI 1.31–3.73; p < 0.001), after adjustment for confounders. Conclusions: Higher PsO disease activity is independently associated with impairment in specific sleep domains, particularly sleep latency and daytime dysfunction, rather than global sleep quality. These findings highlight the importance of assessing domain-specific sleep disturbances and support the integration of sleep outcomes into a holistic, patient-centered approach to PsO management.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-05-29
DOI
https://doi.org/10.3390/jcm15114198
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Disease Activity-Related Sleep Dysfunction in Psoriasis: Insights from a Cross-Sectional Study

Claudio Conforti, Luca Navarini, Marta Vomero, Annalisa Marino et al.
Journal of Clinical Medicine
Psoriasis: Treatment and Pathogenesis
article

Disease Activity-Related Sleep Dysfunction in Psoriasis: Insights from a Cross-Sectional Study

Claudio Conforti, Luca Navarini, Marta Vomero, Annalisa Marino, Damiano Currado, Francesca Saracino, Erika Corberi, Francesca Trunfio, Chiara Retrosi, Onorina Berardicurti, Iris Zalaudek, Roberto Giacomelli
article en

Abstract

Background/Objectives: Psoriasis (PsO) is a chronic immune-mediated disease associated with a substantial multidimensional burden extending beyond skin involvement. Sleep disturbance represents an important yet underexplored domain of patient-reported outcomes. This study aimed to investigate the relationship between PsO disease activity and sleep quality, focusing on specific sleep domains, and to evaluate whether disease severity independently predicts sleep latency and daytime dysfunction. Methods: We conducted a cross-sectional study including 136 consecutive patients with PsO from two Italian centers. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI). Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI), while quality of life was measured by the SF-36. Patients were stratified according to disease severity (PASI < 10 vs. ≥10). Associations between disease activity and sleep domains were analyzed using univariable and multivariable ordinal regression models adjusted for demographic and clinical variables. Results: The study population had predominantly low disease activity (median PASI 2). The median global PSQI score was 5, indicating overall borderline sleep impairment. Patients with PASI ≥ 10 showed significantly worse sleep latency (p = 0.01) and greater daytime dysfunction (p = 0.02), while no significant differences were observed in global PSQI scores. In multivariable analyses, PASI ≥ 10 remained independently associated with increased sleep latency (β = 0.95, 95% CI 0.08–1.82; p = 0.032) and daytime dysfunction (β = 2.52, 95% CI 1.31–3.73; p < 0.001), after adjustment for confounders. Conclusions: Higher PsO disease activity is independently associated with impairment in specific sleep domains, particularly sleep latency and daytime dysfunction, rather than global sleep quality. These findings highlight the importance of assessing domain-specific sleep disturbances and support the integration of sleep outcomes into a holistic, patient-centered approach to PsO management.

Journal of Clinical MedicineVol. 15(11)
University of Trieste (IT), Università Campus Bio-Medico (IT), University of L'Aquila (IT), Istituto Dermopatico dell'Immacolata (IT), Campus Bio Medico University Hospital (IT), Link Campus University (IT)
Good health and well-being
Openalex Percentile: Top 9%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.